𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cost Utility of Sequential Adjuvant Trastuzumab for HER2/Neu-Positive Breast Cancer

✍ Scribed by Shelby D. Reed; Kevin A. Schulman

Book ID
109079018
Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
62 KB
Volume
12
Category
Article
ISSN
1098-3015

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Cost-effectiveness analysis of trastuzum
Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer
✍ Louis P. Garrison Jr; Deborah Lubeck; Deepa Lalla; Virginia Paton; Amylou Dueck; πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 209 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. Adding trastuzumab to adjuvant chemotherapy provides significant clinical benefit in patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer. A cost‐effectiveness analysis was performed to assess clinical and economic implications of adding t